Zobrazeno 1 - 8
of 8
pro vyhledávání: '"MFS Fernandes"'
Autor:
MFS Fernandes, LF Ananias, SCSV Tanaka, LR Soares, MMD Moura, ACDM Carneiro, ML Samuel, BMB Souza, H Moraes-Souza, FB Vito
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S386-S387 (2023)
Objective: The aim of this study was to evaluate the expression of the PDCD1 gene in patients with lymphoma and multiple myeloma regarding disease severity and outcome. Several studies suggest that this gene is overexpressed in multiple types of canc
Externí odkaz:
https://doaj.org/article/49206aa05f034e6282ed48955f9ef09d
Autor:
LF Ananias, LQ Pereira, LR Soares, MFS Fernandes, MBC Mascarenhas, TT Souza, YVC Mascarenhas, HM Souza, FB Vito, SCSV Tanaka
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S696-S697 (2023)
Objetivo: Promover, de forma acessível, a importância e incentivar a doação de sangue, visto os baixos estoques de sangue nos hemocentros. Materiais e métodos: Durante todos os dias de junho, mês dedicado à doação de sangue, foram elaborados
Externí odkaz:
https://doaj.org/article/993809422fcc4518994b127a32d2409a
Autor:
LR Soares, MBC Mascarenhas, MFS Fernandes, SCSV Tanaka, H Moraes-Souza, ACDM Carneiro, FB Vito
Publikováno v:
Hematology, Transfusion and Cell Therapy, Vol 45, Iss , Pp S847- (2023)
Objetivo: Esta pesquisa investigou se o extrato EPs 7630 de Pelargonium sidoides possui a capacidade de aumentar a atividade citotóxica das células natural killer (NK) para eliminar células de linhagem tumoral hematológica. Materiais e métodos:
Externí odkaz:
https://doaj.org/article/cee656d8868f495ea6330bf2ab7a8337
Autor:
Alexe A; Novartis, Rue de La Tour de L`Ile 4, 1204, Geneva, Switzerland. amalia.alexe@novartis.com., Garg A; Sanofi, Bridgewater, USA., Kovacs B; Boehringer Ingelheim Pharmaceuticals, Danbury, USA., Abramova N; Merck Healthcare KGaA, Frankfort, Germany., Apara O; Merck & Co., Inc., Philadelphia, USA., Eisele O; Amgen Inc., Los Angeles, USA., Fernandes MFS; Eli Lilly, Indianapolis, USA., Balramsingh-Harry L; Hoffman LaRoche Ltd., Mississauga, Canada., Wurst K; GlaxoSmithKline, Raleigh, USA., Lewis D; Novartis, Rue de La Tour de L`Ile 4, 1204, Geneva, Switzerland.
Publikováno v:
Therapeutic innovation & regulatory science [Ther Innov Regul Sci] 2024 Mar; Vol. 58 (2), pp. 242-257. Date of Electronic Publication: 2023 Dec 17.
Autor:
Alexe A; Novartis, Lichtstrasse 35, Basel, 4056, Switzerland., Eisele O; Amgen Inc, Los Angeles, California, USA., Fernandes MFS; Eli Lilly, Indianapolis, Indiana, USA., Garg A; Sanofi, Bridgewater, Massachusetts, USA., Kovacs B; Boehringer Ingelheim Pharmaceuticals, Danbury, Connecticut, USA., Wurst K; GlaxoSmithKline, Raleigh, North Carolina, USA., Balramsingh-Harry L; Hoffmann La Roche Ltd, Mississauga, Canada., Abramova N; Merck Healthcare KGaA, Frankfort, Germany., Zheteyeva Y; Merck & Co Inc, Philadelphia, Pennsylvania, USA., Lewis D; Novartis, Lichtstrasse 35, Basel, 4056, Switzerland.
Publikováno v:
British journal of clinical pharmacology [Br J Clin Pharmacol] 2024 Mar; Vol. 90 (3), pp. 715-721. Date of Electronic Publication: 2023 Nov 15.
Autor:
Eke AC; Division of Maternal Fetal Medicine, Department of Gynecology & Obstetrics, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Gebreyohannes RD; Department of Obstetrics and Gynecology, Addis Ababa University College of Medicine, Addis Ababa, Ethiopia., Fernandes MFS; Lilly Corporate Center, Eli Lilly and Company, Indianapolis, Indiana, USA., Pillai VC; United States Food and Drug Administration (FDA), Silver Spring, Maryland, USA.
Publikováno v:
Journal of clinical pharmacology [J Clin Pharmacol] 2023 Jun; Vol. 63 Suppl 1, pp. S34-S50.
Autor:
Ankarfeldt MZ; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Hovedvejen opgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Copenhagen, Denmark. mikkelza@gmail.com., Petersen J; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Hovedvejen opgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Copenhagen, Denmark.; Section for Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Andersen JT; Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Fernandes MFS; Eli Lilly and Company, Indianapolis, IN, USA., Li H; Eli Lilly and Company, Indianapolis, IN, USA., Motsko SP; Eli Lilly and Company, Indianapolis, IN, USA., Fast T; Institute of Applied Economics & Health Research, Copenhagen, Denmark., Jimenez-Solem E; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Hovedvejen opgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Copenhagen, Denmark.; Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Drugs - real world outcomes [Drugs Real World Outcomes] 2023 Mar; Vol. 10 (1), pp. 69-81. Date of Electronic Publication: 2022 Nov 10.
Autor:
Ankarfeldt MZ; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark. Mikkel.Zoellner.Ankarfeldt@regionh.dk.; Center for Clinical Research and Prevention, Frederiksberg Hospital, Hovedvejen Indgang 5, Nordre Fasanvej 57, 2000, Frederiksberg, Denmark. Mikkel.Zoellner.Ankarfeldt@regionh.dk., Petersen J; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Section for Biostatistics, Department of Public Health, University of Copenhagen, Copenhagen, Denmark., Andersen JT; Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark., Fernandes MFS; Eli Lilly and Company, Indianapolis, IN, USA., Li H; Eli Lilly and Company, Indianapolis, IN, USA., Motsko SP; Eli Lilly and Company, Indianapolis, IN, USA., Fast T; Institute of Applied Economics and Health Research, Copenhagen, Denmark., Jimenez-Solem E; Copenhagen Phase IV Unit (Phase4CPH), Department of Clinical Pharmacology and Center for Clinical Research and Prevention, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Department of Clinical Pharmacology, Copenhagen University Hospital Bispebjerg and Frederiksberg, Copenhagen, Denmark.; Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
Publikováno v:
Drugs - real world outcomes [Drugs Real World Outcomes] 2021 Sep; Vol. 8 (3), pp. 289-299. Date of Electronic Publication: 2021 May 18.